A Phase 1/ 2 Study of the TRK Inhibitor LOXO 195 in Adult Subjects With NTRK Fusion (Previously Treated) or Non-Fusion NTRK Altered Cancers
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2017
At a glance
- Drugs LOXO 195 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Loxo Oncology
- 03 Jun 2017 According to a Loxo Oncology media release, clinical proof-of-concept data from the first two patients treated has been published online.
- 03 Jun 2017 Status changed from planning to recruiting, according to a Loxo Oncology media release.
- 30 May 2017 According to a Loxo Oncology media release, the United States Food and Drug Administration has cleared the Investigational New Drug (IND) application for LOXO-195 and planning to initiate Phase 1/2 trial.